Key takeaways
Triumeq (abacavir/dolutegravir/lamivudine) and Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) are both single-tablet regimens used to treat HIV, but they have some key differences. Triumeq contains an integrase inhibitor (dolutegravir) and two nucleoside reverse transcriptase inhibitors (NRTIs) (abacavir and lamivudine), while Complera includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) (rilpivirine) and two NRTIs (emtricitabine and tenofovir). Triumeq can be taken with or without food, but Complera must be taken with a meal. Triumeq requires a genetic test before starting to check for a risk of serious allergic reactions, whereas Complera does not. Complera is not recommended for people with high viral loads or kidney problems, while Triumeq is not suitable for those with moderate to severe liver issues. Both medications can cause liver problems and immune reconstitution syndrome, but Complera also has specific warnings about kidney and bone problems. Triumeq is available in both tablet and dissolvable tablet for children, while Complera is only available as a tablet.
